Incorporating Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The study investigated whether a replacement of neutrophil count and platelet count by neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) within the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model would improve its prognostic accuracy. Materials and Methods This retrospective analysis included consecutive patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. The IMDC and modified-IMDC models were compared using: concordance index (CI), bias-corrected concordance index (BCCI), calibration plots, the Grønnesby and Borgan test, Bayesian Information Criterion (BIC), generalized R2, Integrated Discrimination Improvement (IDI), and continuous Net Reclassification Index (cNRI) for individual risk factors and the three risk groups. Results Three hundred and twenty-one patients were eligible for analyses. The modified-IMDC model with NLR value of 3.6 and PLR value of 157 was selected for comparison with the IMDC model. Both models were well calibrated. All other measures favoured the modified-IMDC model over the IMDC model (CI, 0.706 vs. 0.677; BCCI, 0.699 vs. 0.671; BIC, 2,176.2 vs. 2,190.7; generalized R2, 0.238 vs. 0.202; IDI, 0.044; cNRI, 0.279 for individual risk factors; and CI, 0.669 vs. 0.641; BCCI, 0.669 vs. 0.641; BIC, 2,183.2 vs. 2,198.1; generalized R2, 0.163 vs. 0.123; IDI, 0.045; cNRI, 0.165 for the three risk groups). Conclusion Incorporation of NLR and PLR in place of neutrophil count and platelet count improved prognostic accuracy of the IMDC model. These findings require external validation before introducing into clinical practice.
Abstract
Purpose The study investigated whether a replacement of neutrophil count and platelet count by neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) within the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model would improve its prognostic accuracy. Materials and Methods This retrospective analysis included consecutive patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. The IMDC and modified-IMDC models were compared using: concordance index (CI), bias-corrected concordance index (BCCI), calibration plots, the Grønnesby and Borgan test, Bayesian Information Criterion (BIC), generalized R2, Integrated Discrimination Improvement (IDI), and continuous Net Reclassification Index (cNRI) for individual risk factors and the three risk groups. Results Three hundred and twenty-one patients were eligible for analyses. The modified-IMDC model with NLR value of 3.6 and PLR value of 157 was selected for comparison with the IMDC model. Both models were well calibrated. All other measures favoured the modified-IMDC model over the IMDC model (CI, 0.706 vs. 0.677; BCCI, 0.699 vs. 0.671; BIC, 2,176.2 vs. 2,190.7; generalized R2, 0.238 vs. 0.202; IDI, 0.044; cNRI, 0.279 for individual risk factors; and CI, 0.669 vs. 0.641; BCCI, 0.669 vs. 0.641; BIC, 2,183.2 vs. 2,198.1; generalized R2, 0.163 vs. 0.123; IDI, 0.045; cNRI, 0.165 for the three risk groups). Conclusion Incorporation of NLR and PLR in place of neutrophil count and platelet count improved prognostic accuracy of the IMDC model. These findings require external validation before introducing into clinical practice.
참고문헌 (29)
- Motzer RJ, "Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma", J Clin Oncol, 17, pp.2530~2540 (1999)[DOI]
- Ruiz-Morales JM, "First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium", Eur J Cancer, 65, pp.102~108 (2016)[DOI]
- Heng DY, "Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study", J Clin Oncol, 27, pp.5794~5799 (2009)[DOI]
- Heng DY, "External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study", Lancet Oncol, 14, pp.141~148 (2013)[DOI]
- Ko JJ, "The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study", Lancet Oncol, 16, pp.293~300 (2015)[DOI]
- Wells JC, "Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium", Eur Urol, 71, pp.204~209 (2017)[DOI]
- Templeton AJ, "Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy", Eur Urol, 70, pp.358~364 (2016)[DOI]
- Hu K, "Prognostic role of the neutrophillymphocyte ratio in renal cell carcinoma: a meta-analysis", BMJ Open, 5, pp.e006404~ (2015)[DOI]
- Templeton AJ, "Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT)", J Clin Oncol, 32(4 Suppl) (2014)
- Keizman D, "The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma", Eur J Cancer, 48, pp.202~208 (2012)[DOI]
- Cetin B, "Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?", Clin Genitourin Cancer, 11, pp.141~148 (2013)[DOI]
- Park TJ, "Prognostic significance of platelet-lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer", Springerplus, 5, pp.1889~ (2016)[DOI]
- Chrom P, "Fuhrman grade and neutrophil-to-lymphocyte ratio influence on survival in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors", Clin Genitourin Cancer, 14, pp.457~464 (2016)[DOI]
- Gunduz S, "Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer", Asia Pac J Clin Oncol, 11, pp.288~292 (2015)[DOI]
- Schemper M, "A note on quantifying follow-up in studies of failure time", Control Clin Trials, 17, pp.343~346 (1996)[DOI]
- Contal C, "An application of changepoint methods in studying the effect of age on survival in breast cancer", Comput Stat Data Anal, 30, pp.253~270 (1999)[DOI]
- Harrell FE Jr, "Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors", Stat Med, 15, pp.361~387 (1996)[DOI]
- Gronnesby JK, "A method for checking regression models in survival analysis based on the risk score", Lifetime Data Anal, 2, pp.315~328 (1996)[DOI]
- Pencina MJ, "Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond", Stat Med, 27, pp.157~172 (2008)[DOI]
- Pencina MJ, "Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers", Stat Med, 30, pp.11~21 (2011)[DOI]
- Chambless LE, "Several methods to assess improvement in risk prediction models: extension to survival analysis", Stat Med, 30, pp.22~38 (2011)[DOI]
- Uno H, "A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data", Stat Med, 32, pp.2430~2442 (2013)[DOI]
- Beuselinck B, "Prognostic impact of baseline serum Creactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib", BJU Int, 114, pp.81~89 (2014)[DOI]
- Patil S, "Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma", Ann Oncol, 22, pp.295~300 (2011)[DOI]
- Yildiz I, "Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma", Curr Oncol, 20, pp.e546~e553 (2013)[DOI]
- Fumagalli LA, "Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy", J Immunother, 26, pp.394~402 (2003)[DOI]
- Song W, "Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa", HIF2alpha and estrogen receptor beta signals, 2015, pp.6, 19290~19304
- Uzzo RG, "Mechanisms of apoptosis in T cells from patients with renal cell carcinoma", Clin Cancer Res, 5, pp.1219~1229 (1999)
- Feinstein AR, "The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer", N Engl J Med, 312, pp.1604~1608 (1985)[DOI]